SCHEMBL6776376

SCHEMBL6776376

N=C(N)Nc1cccc(C(=O)NCC(=O)NC(CCO)C(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 5/20 0.45
ITGA2B P08514 1/20 0.45
ITGB1 P05556 5/20 0.43
ITGA5 P08648 5/20 0.43
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ITGAV P06756 4/20 0.42
MDM4 O15151 3/20 0.42
GPR139 Q6DWJ6 7/20 0.42
MDM2 Q00987 3/20 0.42
F10 P00742 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
F2 P00734 1/20 0.39
F7 P08709 1/20 0.39
PRSS1 P07477 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7347747 0.90 ITGB3 (0.47) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL7840867 0.88 ITGB3 (0.46) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL6783191 0.86 ITGB1 (0.42) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL7344206 0.85 HTT (0.48) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL6777468 0.85 ITGB3 (0.44) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL7338510 0.84 GPR139 (0.48) HTTL3MBTL1GPR139F10MEN1
SCHEMBL30083944 0.83 ITGB3 (0.51) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL6777290 0.83 ITGB3 (0.54) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL6780097 0.82 ITGB3 (0.47) ITGB3ITGA2BITGB1ITGA5HTT
SCHEMBL20999541 0.82 ITGB1 (0.54) ITGB3ITGA2BITGB1ITGA5HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed